Expression and cellular immunogenicity of a Transgenic Antigen driven by endogenous poxviral early promoters at their authentic loci in MVA

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Orubu, Toritse ^a   Alharbi, Naif Khalaf ^a   Lambe, Teresa ^a   Gilbert, Sarah C ^a   Cottingham, Matthew G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; RECOMBINANT MODIFIED VACCINIA ANKARA VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CODON; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC STABILITY; HOMOLOGOUS RECOMBINATION; IMMUNOGENICITY; IN VITRO STUDY; KINETICS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OPEN READING FRAME; POXVIRUS; PROMOTER REGION; PSEUDOGENE; TRANSLATION INITIATION; VACCINIA VIRUS; VIROGENESIS;

ANIMALS; ANTIGENS; BASE SEQUENCE; CHROMOSOMES, ARTIFICIAL, BACTERIAL; DNA PRIMERS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; OPEN READING FRAMES; POXVIRIDAE; PROMOTER REGIONS, GENETIC;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; MYCOBACTERIUM TUBERCULOSIS; VACCINIA VIRUS; VACCINIA VIRUS ANKARA;

EID: 84862980937     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040167     Document Type: Article

References (65)

1. Panicali D, Davis SW, Weinberg RL, Paoletti E, (1983) Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A 80: 5364-5368.
2. Smith GL, Mackett M, Moss B, (1983) Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302: 490-495.
3. Smith GL, Murphy BR, Moss B, (1983) Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A 80: 7155-7159.
4. Paoletti E, Lipinskas BR, Samsonoff C, Mercer S, Panicali D, (1984) Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A 81: 193-197.
5. Mackett M, Smith GL, Moss B, (1984) General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol 49: 857-864.
6. Earl PL, Moss B, Wyatt LS, Carroll MW, (1998) Generation of Recombinant Vaccinia Viruses. Current Protocols in Molecular Biology: John Wiley & Sons, Inc pp. 16.17.11-16.17.19.
7. Moss B, (1996) Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A 93: 11341-11348.
8. Gomez CE, Najera JL, Krupa M, Perdiguero B, Esteban M, (2011) MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 11: 189-217.
9. Skinner MA, Laidlaw SM, Eldaghayes I, Kaiser P, Cottingham MG, (2005) Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev Vaccines 4: 63-76.
10. Perkus ME, Limbach K, Paoletti E, (1989) Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol 63: 3829-3836.
11. Wyatt LS, Shors ST, Murphy BR, Moss B, (1996) Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 14: 1451-1458.
12. Chakrabarti S, Sisler JR, Moss B, (1997) Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23: 1094-1097.
13. Sutter G, Moss B, (1992) Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 89: 10847-10851.
14. Wyatt LS, Earl PL, Xiao W, Americo JL, Cotter CA, et al. (2009) Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J Virol 83: 7176-7184.
15. Manuel ER, Wang Z, Li Z, La Rosa C, Zhou W, et al. (2010) Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses. Virology 403: 155-162.
16. Cottingham MG, Andersen RF, Spencer AJ, Saurya S, Furze J, et al. (2008) Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS ONE 3: e1638.
17. Domi A, Moss B, (2002) Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci U S A 99: 12415-12420.
18. Domi A, Moss B, (2005) Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage lambda-based recombination. Nat Methods 2: 95-97.
19. Yang Z, Bruno DP, Martens CA, Porcella SF, Moss B, (2010) Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A 107: 11513-11518.
20. Assarsson E, Greenbaum JA, Sundstrom M, Schaffer L, Hammond JA, et al. (2008) Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A 105: 2140-2145.
21. Rubins KH, Hensley LE, Bell GW, Wang C, Lefkowitz EJ, et al. (2008) Comparative analysis of viral gene expression programs during poxvirus infection: a transcriptional map of the vaccinia and monkeypox genomes. PLoS One 3: e2628.
22. Broyles SS, (2003) Vaccinia virus transcription. J Gen Virol 84: 2293-2303.
23. Davison AJ, Moss B, (1989) Structure of vaccinia virus early promoters. J Mol Biol 210: 749-769.
24. Moss B, Smith GL, Gerin JL, Purcell RH, (1984) Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 311: 67-69.
25. Bennink JR, Yewdell JW, Smith GL, Moller C, Moss B, (1984) Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 311: 578-579.
26. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, et al. (1998) Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4: 397-402.
27. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV, (2011) Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 23: 377-382.
28. Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, et al. (2011) Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. Mol Ther. 19: 2269-76.
29. Loening AM, Fenn TD, Wu AM, Gambhir SS, (2006) Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output. Protein Eng Des Sel 19: 391-400.
30. Romero P, Maryanski JL, Cordey AS, Corradin G, Nussenzweig RS, et al. (1990) Isolation and characterization of protective cytolytic T cells in a rodent malaria model system. Immunol Lett 25: 27-31.
31. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG, (2005) Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 33: e36.
32. Cottingham MG, Gilbert SC, (2010) Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome. J Virol Methods 168: 233-236.
33. Cottingham MG, (2012) Genetic manipulation of poxviruses using bacterial artificial chromosome recombineering. Methods Mol Biol in press.
34. Capone S, Reyes-Sandoval A, Naddeo M, Siani L, Ammendola V, et al. (2010) Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 29: 256-265.
35. Alcock R, Cottingham MG, Rollier CS, Furze J, De Costa SD, et al. (2010) Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med 2: 19ra12.
36. Sridhar S, Reyes-Sandoval A, Draper SJ, Moore AC, Gilbert SC, et al. (2008) Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J Virol 82: 3822-3833.
37. Carter GC, Law M, Hollinshead M, Smith GL, (2005) Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. J Gen Virol 86: 1279-1290.
38. Gomez CE, Najera JL, Krupa M, Esteban M, (2008) The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 8: 97-120.
39. Oseroff C, Peters B, Pasquetto V, Moutaftsi M, Sidney J, et al. (2008) Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve. J Immunol 180: 7193-7202.
40. Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, et al. (2005) Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 201: 95-104.
41. Tscharke DC, Woo WP, Sakala IG, Sidney J, Sette A, et al. (2006) Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol 80: 6318-6323.
42. Sette A, Grey H, Oseroff C, Peters B, Moutaftsi M, et al. (2009) Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens. Vaccine 27: G21-26.
43. Antoine G, Scheiflinger F, Dorner F, Falkner FG, (1998) The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244: 365-396.
44. Mayr A, Stickl H, Muller HK, Danner K, Singer H, (1978) [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol [B] 167: 375-390.
45. Blanchard TJ, Alcami A, Andrea P, Smith GL, (1998) Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79 (Pt 5): 1159-1167.
46. Reading PC, Moore JB, Smith GL, (2003) Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. J Exp Med 197: 1269-1278.
47. Reading PC, Smith GL, (2003) Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J Virol 77: 9960-9968.
48. Buller RM, Chakrabarti S, Moss B, Fredrickson T, (1988) Cell proliferative response to vaccinia virus is mediated by VGF. Virology 164: 182-192.
49. Buller RM, Chakrabarti S, Cooper JA, Twardzik DR, Moss B, (1988) Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol 62: 866-874.
50. Gomez CE, Esteban M, (2001) Recombinant proteins produced by vaccinia virus vectors can be incorporated within the virion (IMV form) into different compartments. Arch Virol 146: 875-892.
51. Krauss O, Hollinshead R, Hollinshead M, Smith GL, (2002) An investigation of incorporation of cellular antigens into vaccinia virus particles. J Gen Virol 83: 2347-2359.
52. Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, et al. (2010) Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 78: 145-153.
53. Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, et al. (2010) Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines. J Immunol 185: 7583-7595.
54. Hopkins R, Bridgeman A, Joseph J, Gilbert SC, McShane H, et al. (2011) Dual neonate vaccine platform against HIV-1 and M. tuberculosis. PLoS One 6: e20067.
55. Wang Z, Martinez J, Zhou W, La Rosa C, Srivastava T, et al. (2010) Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine 28: 1547-1557.
56. Wyatt LS, Earl PL, Vogt J, Eller LA, Chandran D, et al. (2008) Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine 26: 486-493.
57. Baur K, Brinkmann K, Schweneker M, Patzold J, Meisinger-Henschel C, et al. (2010) Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses. J Virol 84: 8743-8752.
58. Wyatt LS, Belyakov IM, Earl PL, Berzofsky JA, Moss B, (2008) Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology 372: 260-272.
59. Perkus ME, Piccini A, Lipinskas BR, Paoletti E, (1985) Recombinant vaccinia virus: immunization against multiple pathogens. Science 229: 981-984.
60. Kreijtz JH, Suzer Y, Bodewes R, Schwantes A, van Amerongen G, et al. (2010) Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model. J Gen Virol 91: 2745-2752.
61. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, et al. (2011) Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 52: 1-7.
62. Hill AV, (2011) Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci: Biological Sciences 366: 2806-2814.
63. Alcami A, Smith GL, (1995) Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 69: 4633-4639.
64. Valderrama F, Cordeiro JV, Schleich S, Frischknecht F, Way M, (2006) Vaccinia virus-induced cell motility requires F11L-mediated inhibition of RhoA signaling. Science 311: 377-381.
65. Brown JP, Twardzik DR, Marquardt H, Todaro GJ, (1985) Vaccinia virus encodes a polypeptide homologous to epidermal growth factor and transforming growth factor. Nature 313: 491-492.